Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGREE: Abatacept in Early Erosive RA
NCT00122382Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2005
- Primary completion
- Feb 2008
- Modality
- Fc-Fusion Proteins
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Abatacept + MTX with Placebo + MTX (2 arms). Primary endpoints: Number of Participants in DAS 28 C-reactive Protein (CRP) Remission at Month 12, Mean Change From Baseline in Radiographic Total Score at Month 12 and 1 more. Started Jul 2005; status: completed.
02
Drugs
abatacept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00122382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00122382.